Suzhou Industrial Park

Home page > category report > Industries & Enterprises


BrightGene recognized by international pharmaceutical markets


Date:   |   Source:       Font Size:    A   A   A

BrightGene Pharmaceutical Co., Ltd. and BrightGene Fine Chemical Co., Ltd, two wholly-owned subsidiaries of BrightGene Bio-Medical Technology Co., Ltd. in SIP, recently passed Good Manufacturing Practice (GMP) check of Pharmaceuticals and Medical Devices Agency (PMDA) for drug. This signifies that BrightGene has mastered operation procedures for MF application and data maintenance, and that BrightGene's GMP quality meets the strict Japanese official requirements. So far, BrightGene has obtained the official GMP certificates for European, American and Japanese pharmaceutical markets.

BrightGene has developed the innovative drugs to treat three main diseases, that is, malignant tumor, chronic diseases such as diabetes, and liver diseases like fatty liver, hepatitis B and liver cirrhosis.


February 14, 2017